ArticleBioinformatics (Oxford, England)2026
GMHAN: a heterogeneous graph attention framework for prioritizing coding and non-coding driver genes.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
motivationCancer, a disease of high complexity. Identifying cancer driver genes is fundamental for elucidating oncogenesis and promoting precision medicine. Currently, most approaches mainly focus on homogeneous gene networks and single-omics data, thereby mainly identifying coding driver genes while ignoring non-coding driver genes.
resultThus, we introduced GMHAN, a novel framework based on HAN. Firstly, we integrated the three types of omics data of genes and PPI network topology feature, together with the multi-dimensional features of miRNAs. Afterwards, we used heterogeneous graph attention networks to obtain deep feature embeddings of genes and miRNAs. Finally, the deep feature embeddings are input multilayer perceptron to obtain the probability that genes and miRNAs being cancer drivers. In a comparative evaluation against seven methods, GMHAN demonstrates better performance across both pan-cancer and cancer-specific datasets, achieving higher scores in AUC and AUPR. It has confirmed its effectiveness in identifying carcinogenic drivers. AVAILABILITY AND IMPLEMENTATION: The source code of GMHAN is available at: https://github.com/mping315/GMHAN and https://doi.org/10.5281/zenodo.20154736.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.